insights_auto
Pse është ulur HELP 2,39%?
Zhytu më thellëchevron_right
HELP:NASDAQ
Cybin Inc
11,42 US$
arrow_downward
-2,39%(-0,28) 1D
11,42 US$
0,00% (0,00)
bedtimeJashtë orarit
Mbyllur: 5 tet, 4:00:01 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për HELP...
Hap
11,50 US$
I lartë
11,74 US$
I ulët
11,23 US$
Vëllimi mesatar
1,72 mln
Vëllimi
1,31 mln
Maksimumi 52-javor
15,15 US$
Minimumi 52-javor
3,76 US$
Beta
0,53
Aksionet në qarkullim
73,06 mln
Numri i punonjësve
100
Hap
11,50 US$
I lartë
11,74 US$
I ulët
11,23 US$
Vëllimi mesatar
1,72 mln
Vëllimi
1,31 mln
Maksimumi 52-javor
15,15 US$
Minimumi 52-javor
3,76 US$
Beta
0,53
Aksionet në qarkullim
73,06 mln
Numri i punonjësve
100
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
TipRanks
·
5 orë më parë
Helus Pharma Files October Form 6-K and Corporate Amendment with U.S. SEC
Profili
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Rreth Cybin Inc
Drejtori ekzekutiv-
Punonjësit100
Themeluar më2019
SeliaToronto, Ontario, Kanada
Sektori-
Uebsajtihelus.com